Takeda, Schrödinger form research collaboration

Friday, July 21, 2017

Takeda Pharmaceutical and Schrödinger, a privately held company dedicated to revolutionizing drug discovery through advanced computational methods, announced the formation of a multi-target research collaboration directed to diseases that align with Takeda’s core therapeutic areas of interest. The unique collaboration will combine Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. With a focus on simplicity, speed and agility, Schrödinger will lead the multi-target discovery effort with Takeda providing protein crystal structures to aid Schrödinger in using its computational platform to guide the design of new chemical entities. Schrödinger will be responsible for its discovery costs.

[Read More]

Sanofi, Schrödinger ink $120M drug design pact

Friday, April 3, 2015

Schrödinger, a global provider of advanced molecular simulations and enterprise software solutions and services for life sciences and materials research, has entered into a collaboration with Sanofi in which Schrödinger will provide comprehensive computational drug design support, from target analysis and validation to lead identification and lead optimization, for as many as ten drug discovery programs. Schrödinger could receive up to $120 million under the terms of the broad, multi-year relationship that includes preclinical milestones.

[Read More]

Schrödinger and ChemAxon extend partnership

Thursday, July 11, 2013

Schrödinger, a drug discovery solutions company, and ChemAxon, a provider of cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries, have extended their partnership agreement for another five years. ChemAxon will provide the JChem chemistry engine as well as Marvin sketching and rendering functionality to Schrödinger’s enterprise informatics platform, Seurat.

[Read More]